Related Experiment Video
Updated: May 13, 2025

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
Published on: October 13, 2023
Immune microenvironment and molecular mechanisms in endometrial cancer: implications for resistance and innovative
Yijia Chen1, Lai Jiang1, Lanyue Zhang1
1Clinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Abstract:
This review provides a systematic overview of the molecular mechanisms of endometrial cancer and its drug resistance, particularly involving the aberrant activation of some key signaling pathways. These molecular mechanisms significantly affect the therapeutic outcome of endometrial cancer by promoting tumor cell proliferation, anti-apoptosis, and drug resistance. The article also analyzes the critical role of the immune microenvironment in cancer drug resistance, focusing on the impact of immune cells, immune checkpoints, and hypoxic metabolic reprogramming on anticancer therapies. In recent years, immunotherapy and individualized therapy have shown promising clinical outcomes, especially in advanced endometrial cancer. This article summarizes recent advances in related therapeutic strategies and proposes emerging therapeutic strategies by targeting key pathways and modulating the immune microenvironment to overcome drug resistance and improve patient prognosis.
Insights
This review explores endometrial cancer
Area of Science:
- Oncology
- Molecular Biology
Background:
- Endometrial cancer drug resistance is driven by aberrant signaling pathways.
- The tumor immune microenvironment critically influences therapeutic outcomes.
- Hypoxic metabolic reprogramming impacts anticancer therapies.
Purpose of the Study:
- To systematically review molecular mechanisms of endometrial cancer and drug resistance.
- To analyze the role of the immune microenvironment in cancer drug resistance.
- To summarize advances in immunotherapy and individualized therapy for endometrial cancer.
Main Methods:
- Systematic review of molecular mechanisms.
- Analysis of signaling pathways and immune microenvironment.
- Summary of recent therapeutic strategies.
Main Results:
- Aberrant signaling pathways promote tumor proliferation, anti-apoptosis, and drug resistance.
- Immune cells, checkpoints, and hypoxia significantly affect drug resistance.
- Immunotherapy and individualized therapy show promise in advanced endometrial cancer.
Conclusions:
- Targeting key pathways and modulating the immune microenvironment can overcome drug resistance.
- Emerging therapeutic strategies aim to improve patient prognosis in endometrial cancer.
Related Concept Videos
The Tumor Microenvironment
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

